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Abstract 
Background: Inhibitory molecules in the adult central nervous system, including NogoA, impede neural repair by 
blocking axon outgrowth. The actin-myosin regulatory protein Shroom3 directly interacts with Rho kinase and con-
veys axon outgrowth inhibitory signals from Nogo66, a C-terminal inhibitory domain of NogoA. The purpose of this 
study was to identify small molecules that block the Shroom3–Rho kinase protein–protein interaction as a means to 
modulate NogoA signaling and, in the longer term, enhance axon outgrowth during neural repair.
Results: A high throughput screen for inhibitors of the Shroom3–Rho kinase protein–protein interaction identified 
CCG-17444 (Chem ID: 2816053). CCG-17444 inhibits the Shroom3–Rho kinase interaction in vitro with micromolar 
potency. This compound acts through an irreversible, covalent mechanism of action, targeting Shroom3 Cys1816 to 
inhibit the Shroom3–Rho kinase protein–protein interaction. Inhibition of the Shroom3–Rho kinase protein–protein 
interaction with CCG-17444 counteracts the inhibitory action of Nogo66 and enhances neurite outgrowth.
Conclusions: This study identifies a small molecule inhibitor of the Shroom3–Rho kinase protein–protein interac-
tion that circumvents the inhibitory action of Nogo66 in neurons. Identification of a small molecule compound that 
blocks the Shroom3–Rho kinase protein–protein interaction provides a first step towards a potential new strategy for 
enhancing neural repair.
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Background
The axon outgrowth inhibitory protein NogoA limits 
neural regeneration in the adult central nervous system 
[1–3]. Circumventing the action of NogoA with peptide 
antagonists, anti-NogoA antibodies, or soluble receptor 
fragments increases axon outgrowth and neural plastic-
ity, resulting in improved functional recovery after stroke 
[4–7]. Behavioral recovery after stroke is also enhanced 
in knockout animals deficient in NogoA or receptors for 
NogoA [4, 8].
Nogo receptor 1 (NgR1) and paired immunoglobulin-
like receptor B (PirB) are two distinct cell surface recep-
tors that interact with Nogo66, a C-terminal 66 amino 
acid inhibitory domain of NogoA [9, 10]. NgR1 partners 
with LINGO-1 and p75 or TROY [11, 12]. Upon Nogo66 
engagement of this receptor complex, calcium levels 
increase and RhoA and its effector Rho kinase are acti-
vated, leading to destabilization of the actin cytoskeleton 
and growth cone collapse [13]. Despite being structur-
ally unrelated to NgR1, PirB also binds Nogo66 with high 
affinity, and Nogo66-PirB signaling inhibits neurite out-
growth [9, 14]. In addition to acting as a receptor for 
NogoA, PirB and its human ortholog leukocyte immuno-
globulin-like receptor, subfamily B, member 2 (LILRB2) 
are receptors for beta amyloid; interaction of beta amy-
loid with PirB/LILRB2 impairs synaptic plasticity and 
enhances synaptic loss, suggesting a contribution to Alz-
heimer’s disease pathology [15].
PirB mediates Nogo66 neurite outgrowth inhibition 
through an intracellular signaling complex organized by 
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the scaffold protein plenty of SH3s (POSH; also known 
as Sh3rf1) [14, 16]. This signaling complex includes the 
actin-myosin regulator Shroom3, Rho kinase, and leu-
cine zipper kinase (LZK or MAP3K12) [14, 16]. Shroom3 
directly binds to Rho kinase [16–19]. The Shroom3 inter-
action domain is located in a central coiled coil region 
of Rho kinase, directly upstream of the RhoA binding 
domain [18, 19]. Ectopic expression of this domain of Rho 
kinase disrupts the interaction of endogenous Shroom3 
and Rho kinase and in neurons expression of this domain 
enhances neurite outgrowth [16, 19, 20]. This observa-
tion points to an important role for the Shroom3–Rho 
kinase protein–protein interaction in negatively regulat-
ing neurite outgrowth.
Here we report the identification and characterization 
of the first class of chemical inhibitors of the Shroom3–
Rho kinase protein–protein interaction. A biochemical 
screen of 20,000 diverse chemical compounds identi-
fied nine potent inhibitors of the Shroom3–Rho kinase 
protein–protein interaction. Among these, CCG-17444 
enhanced neurite outgrowth and circumvented Nogo66 
inhibition in neurons. This compound binds covalently 
to Shroom3 and interferes with its ability to interact 
with Rho kinase. The identification of a small molecule 
compound that blocks the Shroom3–Rho kinase pro-
tein–protein interaction provides a first step towards a 
potential new strategy for neural repair.
Results
High throughput screen for Shroom3–Rho kinase 
inhibitors
Shroom3 and Rho kinase directly interact through the 
SD2 domain of Shroom3 and the R2-C1 domain of Rho 
kinase 2 (ROCK2) (Figure 1a). An enzyme linked immu-
nosorbent assay (ELISA) platform was developed to 
detect the interaction of these two domains. Bacterially 
purified, unlabeled SD2 (aa 1,563–1,986) was directly 
immobilized on the surface of high binding 384 well 
microplates. R2-C1 (aa 698–957) was biotinylated. By 
varying the concentration of biotinylated R2-C1 with 
a fixed concentration of SD2, the apparent Kd was cal-
culated to be 4.9 ± 0.3 nM (Kd ± SEM) (Figure 1b). To 
determine if binding of R2-C1 to SD2 was specific, a 
competition assay was performed. Unlabeled R2-C1 
effectively competed with biotinylated R2-C1 for bind-
ing to immobilized SD2 (Figure  1c), demonstrating that 
Figure 1 Shroom3 and Rho kinase interact with high affinity. a A schematic overview of the Shroom3 and ROCK II domain architecture. R2C1 is 
the Shroom binding domain (SBD) of ROCK II. Shroom domain (SD) 2 is the ROCK interacting domain of Shroom3. In these studies, R2C1 and SD2 
encode amino acids 698–957 and 1,563–1,986 of ROCK II and Shroom3, respectively. b Shroom3 and ROCK II interact with nM affinity (Kd ± SEM, 
n = 8). c Unlabeled R2C1 competes with biotin labeled R2C1 for association with SD2 in a dose dependent manner (n = 4, *p < 0.05, Student’s t 
test).
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the interaction assayed in the ELISA is due to specific 
binding of SD2 with R2-C1. The Z’ factor of the ELISA, a 
measure of assay dynamic range and variation, was 0.74, 
indicating the suitability of the SD2/R2-C1 ELISA plat-
form for screening.
To identify inhibitors of the Shroom3/ROCK2 protein–
protein interaction, 20,000 small molecule compounds 
were screened using the ELISA platform. Initial hits were 
defined as showing a signal that is greater than or equal 
to three standard deviations from the mean negative con-
trol per individual plate, e.g. greater than 20–30% inhibi-
tion (% effect). The primary screen of 20,000 compounds 
yielded 180 compounds for a 0.9% hit rate (Table 1).
Dose response analysis was performed with 180 hits 
from the primary screen. Compounds that titrated in dose 
response were triaged using % off-target effects, efficacy 
at maximum dose tested, and pIC50 values. By applying a 
stringent cutoff of greater than 60% inhibition in the ELISA 
and pIC50 values greater than 3.5, 36 candidate inhibitors 
of the Shroom3/ROCK2 protein–protein interaction were 
identified. 32 of the 36 were available for resupply.
A follow-up dose response assay was performed using 
fresh powder samples. 27 compounds reconfirmed as 
hits and nine compounds had IC50 values of less than 
30  μM. These nine compounds were tested for their 
ability to enhance neurite outgrowth in neurons, as 
hypothesized for an inhibitor of the NogoA signaling 
pathway. One compound, CCG-17444, enhanced neur-
ite outgrowth (discussed below) and was defined as the 
primary hit from the screen (Figure 2a). CCG-17444 
inhibited the Shroom3–ROCK interaction with an IC50 
value of 12.4  ±  2.3  μM (IC50  ±  SEM) (Figure  2b). To 
assess cytotoxicity, P19 neurons were treated with 25 μM 
CCG-17444 or DMSO vehicle control for 24 h and toxic-
ity assessed using a resazurin-based assay that measures 
cellular reducing potential (Alamar blue). No increase in 
cytotoxicity was observed in CCG-17444 treated neu-
rons relative to DMSO control treated neurons (data not 
shown). 
CCG‑17444 enhances neurite outgrowth
NogoA signals to the POSH/Shroom3/Rho kinase sign-
aling complex to limit neurite outgrowth in cultured 
neurons [14]. Therefore, we hypothesized that pharmaco-
logical inhibition of the Shroom3/ROCK2 protein–pro-
tein interaction with CCG-17444 would relieve neurite 
outgrowth inhibition, as observed for RNA interference 
(RNAi) mediated reduction of POSH or Shroom3 func-
tion [14, 16]. To test this hypothesis, we examined the 
effect of compound treatment on neurite outgrowth in 
differentiated neurons derived from mouse P19 embry-
onic carcinoma cells [14, 16, 21, 22]. Neurons were gener-
ated by transfection with the neural basic helix-loop-helix 
protein Neurogenin 2 (Ngn2) [16, 21]. Control, Shroom3, 
or POSH RNAi vectors were co-transfected with Ngn2. 
48 h after transfection, neurons were treated with vehicle 
control (DMSO) or 25 μM CCG-17444. 24 h later, neu-
rons were fixed and stained for green fluorescent protein 
(GFP), which identifies the transfected neurons, and neu-
rite outgrowth analyzed. P19-derived neurons treated 
with CCG-17444 exhibited an increase in neurite length 
relative to control treated neurons, similar to the increase 
observed for neurons with an RNAi-mediated decrease 
in POSH or Shroom3 (Figure 3a, b). P19-derived neurons 
treated with CCG-17444 at concentrations below 25 μM 
(e.g. 6.25 or 12.5 μM) did not exhibit an increase in neur-
ite length relative to control DMSO treated neurons, and 
drug treatment at 50 μM increased neurite length to the 
same extent as 25 μM (data not shown).
To probe the mode of action of CCG-17444, we deter-
mined the effect of compound addition on neurite length 
for neurons expressing POSH or Shroom3 RNAi vec-
tors. If the compound and RNAi operate on different 
signaling pathways to enhance neurite outgrowth, then 
compound addition and RNAi are expected to work addi-
tively or cooperatively to enhance neurite outgrowth. In 
contrast to control neurons, neurons expressing POSH 
or Shroom3 RNAi vectors did not exhibit an additional 
increase in neurite length upon CCG-17444 treatment 
(Figure 3b). This result suggests that the compound and 
RNAi operate on the same signaling pathway to regulate 
neurite length, supporting the hypothesis that CCG-
17444 inhibits the Shroom3–Rho kinase signaling com-
plex to limit neurite outgrowth.
CCG‑17444 is an irreversible inhibitor of the Shroom3–
ROCK protein–protein interaction
CCG-17444 (Figure  2a) could potentially function as a 
Michael acceptor; therefore, the activity of CCG-17444 
Table 1 Summary of high throughput screening results
A 20,000 compound library was screened using the ELISA platform as described 
in Materials and Methods. 180 compounds were subject to dose response analy-
sis. Of these 36 inhibited the Shroom3–ROCK interaction with pIC50 values 
greater than 4.0, had >60% efficacy at maximum dose tested, and had recov-
ery rates in unrelated screens at <22%. 32 of the 36 chemicals were available 
for repurchase and of these 27 reconfirmed as inhibitors of the Shroom3–ROCK 
interaction. Nine compounds of the 27 confirmed hits have IC50 values less than 
30 μM. One compound enhances neurite outgrowth.
Total # compounds screened 20,000
Hits from primary screen 180 (0.9%)
Dose response 36 (0.18%)
Available for re-supply 32 (0.16%)
Confirmed inhibitors 27 (0.14%)
IC50 <30 μM 9 (0.05%)
Enhanced neurite outgrowth 1 (0.005%)
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in the presence of DTT was determined. The addition 
of DTT completely blocked the ability of CCG-17444 to 
inhibit the Shroom3–ROCK2 protein–protein interac-
tion (Figure  4a), suggesting that CCG-17444 functions 
as a cysteine thiol reactive Michael acceptor, potentially 
modifying a sulfhydryl residue in one of the interacting 
partners. To test the reversibility of the interaction, CCG-
17444 was incubated with the Shroom3 SD2 domain, the 
compound was then diluted and washed away prior to 
the addition of the ROCK R2-C1 domain. Diluting and 
washing away the compound had no effect on the ability 
of CCG-17444 to inhibit the protein–protein interaction 
(Figure 4b), indicating that CCG-17444 acts through an 
irreversible, covalent mechanism of action. In addition, 
this result identifies the Shroom3 SD2 domain as the 
target of the compound since the wash step occurs after 
incubation of compound with the Shroom3 SD2 domain 
and prior to addition of ROCK R2-C1.
To further examine the role of cysteine residues in 
the mechanism of action of CCG-17444, site directed 
mutagenesis was employed. The SD2 core domain (aa 
1,762–1,952), which is sufficient to bind ROCK [18], 
contains two cysteine residues and each was mutated 
to alanine, individually or in combination. SD2 Cys 254 
corresponds to Cys 1816 in full length mouse Shroom3 
(accession number AAF13269); SD2 Cys379 corresponds 
to mouse Shroom3 Cys1941. CCG-17444 inhibited the 
ability of SD2 Cys379Ala to interact with R2-C1, indis-
tinguishable from wild type (Figure 4c). In contrast, the 
interaction of SD2 Cys254Ala with R2-C1 was resistant 
to CCG-17444, identifying Cys254 in SD2 as the site of 
action of CCG-17444. Although resistant to drug inhibi-
tion, SD2 Cys254Ala bound to R2-C1 to a similar extent 
as SD2 wild type (Figure 4c). The interaction of the double 
mutant SD2 Cys254Ala Cys379Ala was indistinguishable 
from the single mutant Cys254Ala. These results identify 
SD2 Cys254 (mouse Shroom3 Cys1816) as the primary 
site of action of CCG-17444 and support the hypothesis 
that CCG-17444 interferes with the Shroom3–ROCK2 
protein–protein interaction by forming a covalent adduct 
with cysteine 254 in the SD2 domain of Shroom3.
To further test the hypothesis that CCG-17444 regu-
lates neurite outgrowth through its interaction with 
Shroom3, neurons overexpressing Shroom3 (aa 1,762–
1,986), which includes the SD2 core domain, were treated 
with CCG-17444 and neurite outgrowth analyzed. We 
reasoned that overexpression of SD2, the target of the 
compound should titrate, or sequester, the compound 
away from the endogenous Shroom3–Rho kinase com-
plex, preventing CCG-17444 from enhancing neurite 
outgrowth. Neurons transfected with a control vector 
exhibited an increase in neurite length when treated with 
CCG-17444 (Figure  5). DMSO treated neurons overex-
pressing SD2 (Shroom3 aa 1,762–1,986) exhibited a mod-
est increase in neurite length relative to DMSO treated 
neurons transfected with a control vector, an increase 
from 123  ±  8 to 133  ±  11  μm (neurite length  ±  SD, 
p < 0.01). This increase may be due to this domain exert-
ing a weak dominant negative effect, potentially by inter-
fering with the interaction of endogenous Shroom3 and 
Rho kinase. Consistent with the hypothesis being tested, 
overexpression of SD2 reversed the action of CCG-17444, 
as neurite length of CCG-17444 treated SD2 express-
ing neurons was indistinguishable from DMSO treated 
SD2 expressing neurons. Notably, neurite outgrowth 
was increased in neurons overexpressing a mutant SD2 
domain unable to bind CCG-17444, Cys254Ala. The 
observation that ectopic expression of wild type but not 
mutant SD2 reversed the action of CCG-17444 supports 
the hypothesis that CCG-17444 enhances neurite out-
growth by interfering with the function of the Shroom3 
SD2 domain.
CCG‑17444 relieves neurite outgrowth inhibition 
by Nogo66
Based on our published studies that demonstrated 
that Nogo66 signals through the PirB receptor to the 
Figure 2 CCG-17444 inhibits the Shroom3–ROCK II protein–protein 
interaction. a Chemical structure of CCG-17444 (Chem ID: 2816053). b 
CCG-17444 inhibits the Shroom3–ROCK II interaction with an IC50 of 
12.4 ± 2.3 (IC50 ± SEM, n = 3).
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POSH complex to limit neurite outgrowth [14], we 
hypothesized that chemical inhibitors that disrupt the 
Shroom3–ROCK protein–protein interaction in vitro 
would counteract the action of Nogo66 in neurons. To 
test this hypothesis, primary cerebellar granule neu-
rons (CGNs) were prepared from postnatal day 8 mice 
and nucleofected with an expression vector for GFP to 
facilitate quantitative determination of neurite length of 
individual neurons. Nucleofected CGNs were plated to 
poly-l-lysine/laminin (control) or poly-l-lysine/laminin 
plus Nogo66. Six hours after nucleofection and plat-
ing, compounds were added and, 24  h later, neurons 
were fixed and processed for determination of neurite 
length. Neurons treated with CCG-17444 show enhanced 
neurite length on the inhibitory substrate Nogo66 rela-
tive to control neurons (Figure 6). Consistent with previ-
ous reports [23, 24], neurons treated with the Rho kinase 
inhibitor Y27632 (positive control) show an increase in 
neurite length relative to control neurons in the pres-
ence of Nogo66. Thus, pharmacological inhibition of 
the endogenous Shroom3–Rho kinase protein–protein 
interaction with CCG-17444 enables primary neurons to 
overcome growth mediated inhibition by Nogo66.
Discussion
Employing a chemical screening methodology, we iden-
tified a small molecule inhibitor of the Shroom3–Rho 
kinase protein–protein interaction CCG-17444 that 
Figure 3 Inhibition of the Shroom3–ROCK protein–protein interaction with CCG-17444 enhances neurite outgrowth. P19-derived neurons were 
treated with 25 μM CCG-17444 or vehicle control (DMSO) for 24 h. a, b CCG-17444 enhances neurite length in neurons transfected with an RNAi 
control vector. Neurons transfected with POSH RNAi or Shroom3 RNAi vectors exhibit enhanced neurite length due to reduction of POSH or 
Shroom3 function but CCG-17444 does not further enhance neurite length, suggesting that CCG-17444 selectively targets the POSH/Shroom3 
signaling complex (n = 3). Student’s t test: *p < 0.0001, Control RNAi vs CCG-17444 treated Control RNAi; #p < 0.0001, Control RNAi vs Shroom3 or 
POSH RNAi; **p < 0.0005, CCG-17444 Control RNAi vs CCG-17444 Shroom3 RNAi; +p < 0.0001, CCG-17444 Control RNAi vs CCG-17444 POSH RNAi. 
Scale bar 100 μm.
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exhibits micromolar potency. The Shroom3–Rho kinase 
signaling complex, together with the POSH scaffold 
protein, relays Nogo66-mediated neurite outgrowth 
inhibition [14, 16]. Importantly, neurons treated with 
CCG-17444 are refractory to the inhibitory action of 
Nogo66. To our knowledge, this is the first identifica-
tion of a small molecule chemical compound that relieves 
Nogo66 inhibition by disrupting a protein–protein inter-
action in an intracellular signal transduction complex.
CCG-17444 was identified on the basis of its ability to 
interfere with the interaction of Shroom3 and Rho kinase 
in vitro. Three observations indicate that the compound 
targets the Shroom3–Rho kinase signaling complex in 
vivo. First, genetic inhibition of the POSH/Shroom3/Rho 
kinase signaling pathway in neurons has a comparable 
outcome to CCG-17444 treatment. Namely, CCG-17444 
relieves Nogo66 inhibition, as does RNAi-mediated 
reduction of POSH or Shroom3. Second, CCG-17444 
fails to enhance neurite outgrowth in neurons deficient in 
either Shroom3 or POSH function, indicating that com-
pound and RNAi target the same, not different, signaling 
pathways to enhance neurite outgrowth. Third, cellular 
Figure 4 A single cysteine residue in the Shroom3 SD2 domain is required for CCG-17444 activity. a CCG-17444 activity is blocked by DTT. To inves-
tigate a thiol sensitive mechanism, DTT was added after plating SD2 and was present at all subsequent steps in the ELISA. (n = 3, p < 0.001, Stu-
dent’s t test). b CCG-17444 is an irreversible inhibitor. After plating, SD2 was treated with CCG-17444 then wells were washed extensively to remove 
unbound compound prior to addition of R2-C1 (n = 3). c Cys254 of SD2 is the site of action of CCG-17444. CCG-17444 inhibits the interaction of 
WT SD2 with the ROCK R2-C1 domain but does not inhibit the interaction of SD2 Cys254Ala with ROCK (upper left panel). WT and Cys254Ala SD2 
interact to similar extent with ROCK (upper right panel). CCG-17444 inhibits the interaction of SD2 Cys379Ala with R2-C1, suggesting that Cys379A 
is not a site of drug action (lower left panel). The double Cys to Ala mutant is indistinguishable from the single Cys254Ala mutant (lower right panel), 
indicating a single site of action of CCG-17444 (n = 3).
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overexpression of wild type but not Cys254 mutant SD2 
core domain reverses the action of CCG-17444 on neu-
rite outgrowth, consistent with the overexpressed SD2 
domain acting as a sink to titrate the compound away 
from the endogenous Shroom3–Rho kinase complex. 
We conclude that CCG-17444 circumvents neurite out-
growth inhibition by Nogo66 by interfering with the 
POSH/Shroom3/ROCK signaling pathway.
The chemical structure of CCG-17444 suggests that it 
has potential to function as a Michael acceptor, under-
going a nucleophilic attack by a free sulfhydryl of a 
Michael donor cysteine. Consistent with this, inhibition 
of the Shroom3 SD2/Rho kinase R2-C1 protein–protein 
interaction by CCG-17444 is blocked by the addition 
of DTT and is irreversible. Moreover, CCG-17444 does 
not inhibit the interaction between SD2 Cys254Ala and 
R2-C1, identifying Cys254 of SD2 (Cys 1816 of mouse 
Shroom3) as the site of action of the compound. On the 
basis of these observations, CCG-17444 is proposed to 
function by a covalent mechanism, with the compound 
binding to Cys254 of the SD2 domain of Shroom3 
Figure 5 Overexpression of SD2 in neurons blocks CCG-17444 
activity. P19-derived neurons were transfected with a control vector 
or SD2 expression vector (Shroom3 aa 1,762–1,986) and treated with 
DMSO (vehicle control) or 25 μM CCG-17444 for 24 h prior to analysis 
of neurite length. Ectopic expression of wild type but not Cys254Ala 
SD2 reverses the action of CCG-17444, demonstrating that the 
mechanism of action of CCG-17444 in neurons is inhibition of SD2 
function (n = 3, *p < 0.0001, **p < 0.05 Student’s t test).
Figure 6 CCG-17444 enhances neurite outgrowth in CGNs and counteracts the inhibitory action of Nogo66. Postnatal d8 CGNs were treated for 
24 h with CCG-17444, vehicle control, or the ROCK inhibitor Y27632 (positive control). a Nogo66 inhibits neurite outgrowth in CGNs, and CCG-17444 
counteracts this inhibition. Scale bar 100 μm. b Quantitation of neurite length. Data are mean ± SD (n = 3, *p < 0.0001, Student’s t test).
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to inhibit the interaction between Shroom3 and Rho 
kinase.
In vertebrates, two additional Shroom family members, 
Shroom2 and Shroom4, have been identified. Shroom 
proteins regulate cytoskeletal architecture and have 
important but distinct roles in development. Shroom3 
regulates neural tube closure whereas Shroom2 regulates 
morphogenesis of the vasculature [25, 26]. In addition, 
Shroom2 regulates egg pigmentation in amphibians and 
melanosome biogenesis and pigmentation in the Xeno-
pus eye [27, 28]. Mutations in Shroom4 have been linked 
to intellectual disability [29–32]. Shroom proteins have 
a conserved SD2 domain and interact with Rho kinase 
to regulate cell shape and tissue architecture [25, 33, 
34]. The cysteine targeted by CCG-17444 in Shroom3 is 
also present in Shroom2 and Shroom4. However, addi-
tion of CCG-17444 has no further effect on the Shroom3 
RNAi phenotype (Figure  3), suggesting that Shroom2 
and/or Shroom4, if expressed in P19-derived neurons, 
are not playing a significant role in Nogo66 regulated 
neurite outgrowth inhibition. Whether CCG-17444 
inhibits the interaction of Shroom2 and Shroom4 with 
ROCK in other contexts in vitro or in vivo remains to be 
determined.
The SD2 domain of Drosophila Shroom (dShrm) is a 
three-segmented coiled-coil dimer with internal symme-
try [18]. Cys254 in SD2, conserved in mouse (accession 
number: AAF13269) and human, is equivalent to dShrm 
Val1446, which is located at the bend linking HelixA to 
HelixB. Based on the model proposed by Mohan et  al. 
[18] that the SD2 dimer undergoes a conformational 
change upon binding to Rho kinase centered on the 
inflection point of internal symmetry, we propose that 
CCG-17444 blocks the interaction of Shroom3 and Rho 
kinase by an allosteric inhibitory mechanism.
Protein–protein interactions are prevalent and central 
to many biological processes but present unique chal-
lenges for probe and drug discovery efforts, including 
large, relatively flat surface areas and low affinity [35, 36]. 
Despite presenting unique challenges, there has been an 
increase in the discovery of small molecules that target 
protein–protein interactions. A large fraction of these 
target protein–protein interactions with tight affinities 
(<1  μM) and small surface areas [37]. Consistent with 
this paradigm, Shroom3 and Rho kinase interact with a 
relatively tight affinity (4.9 nM for mouse Shroom3/Rho 
kinase II); however, CCG-17444 interacts with a specific 
Cys residue, potentially blocking an allosteric change, 
so small surface area across the protein–protein inter-
face does not appear to be a major determinant in this 
case. Thus, small molecule compounds are likely to block 
protein–protein interactions through diverse modes of 
action.
NogoA/Nogo66, EphrinA5, and chondroitin sulfate 
proteoglycans converge on the RhoA/Rho kinase sign-
aling pathway and actively prevent axonal growth after 
injury [2, 3, 38, 39]. Blockade of these axon outgrowth 
inhibitors with antibodies that block receptor function, 
competitive peptide antagonists, or soluble receptor 
decoys enhances functional recovery after CNS injury 
[4–7, 39]. Distinct from strategies that block receptor 
function, CCG-17444 inhibits a critical protein–protein 
interaction within a key intracellular signaling hub that 
regulates neurite outgrowth inhibition, the interaction 
between Shroom3 and Rho kinase. Rho kinase regulates a 
diverse array of biological outcomes [40–42] so precisely 
blocking Rho kinase activity in a signaling complex dedi-
cated to regulating neurite outgrowth inhibition, rather 
than all Rho kinase enzymatic activity, is likely to be more 
specific and less prone to off-target effects. A significant 
contributor to disability after CNS injury is the failure of 
the adult CNS to undergo neural repair. Blocking pro-
tein–protein interactions within specific signaling hubs 
may provide new avenues for enabling neural repair in 
the damaged CNS.
Conclusions
We identified the first small molecule inhibitor of the 
Shroom3–Rho kinase protein–protein interaction. 
Blocking the interaction of Shroom3 with Rho kinase in 
neurons with CCG-17444 circumvents Nogo66 inhibi-
tion in neurons. This study demonstrates the feasibility 
of targeting an intracellular signaling hub as well as pro-
tein–protein interactions to counteract Nogo66 signal-
ing, indicating new directions for neural repair strategies.
Methods
Recombinant proteins
GST-SD2, a GST fusion to the mouse Shroom3 SD2 
domain (aa 1,563–1,986) expressed in pGST-SD2, and 
HisSUMO-R2C1, a His-Sumo epitope fusion to mouse 
ROCK R2C1 (aa 698–957) were produced in Escheri-
chia coli. Briefly, E. coli were lysed by sonication in 
PBS+ buffer (GST purification: PBS with 0.1  mM phe-
nylmethylsulfonyl fluoride, 14  µg/mL aprotinin, 0.1% 
β-mercaptoethanol, 1  µM leupeptin, 1  µM pepstatin) 
(His purification: PBS with 0.1 mM phenylmethylsulfonyl 
fluoride, 14  µg/mL aprotinin, 0.1% β-mercaptoethanol, 
1 µM leupeptin, 1 µM pepstatin, 25 mM imidazole). Tri-
ton X-100 was added to the lysate at 1% of the final vol-
ume. Lysates were incubated with prewashed glutathione 
agarose or HisPur Ni-NTA resin (Thermo Scientific) for 
1 h at 25°C. Purified protein was eluted with GST elution 
buffer (50  mM Tris buffer with 100  mM reduced glu-
tathione, pH 8) or His elution buffer (PBS+ with 250 mM 
Imidazole). HisSUMO-R2C1 was dialyzed overnight at 
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4°C in PBS and stored in 25% glycerol at −20°C. GST-
SD2 was dialyzed for 3 h at 4°C in PBS with three buffer 
changes. The GST epitope tag was removed using His-
TEV (S219V)-Arg Protease overnight at a concentration 
of 1 µg TEV protease per 100 µg of GST-SD2. TEV pro-
tease and free GST was removed from purified SD2 by 
incubation overnight at 4°C with prewashed glutathione 
agarose and HisPur Ni-NTA resin. SD2 was stored at 
−20°C in 25% glycerol.
HisSUMO-R2C1 was biotinylated (NHS-PEO4-Bioti-
nylation Kit, Pierce). Briefly, biotinylation reactions were 
carried out at a 20:1 molar ratio of NHS-PEO4-biotin to 
HisSUMO-R2C1 in PBS (pH 7.4). HisSUMO-R2C1 was 
labeled for 2 h at 4°C. After the incubation, the unreacted 
NHS-PEO4-biotin was removed with buffer exchange in 
PBS (pH 7.4) using Zeba Desalt Spin Columns (2  mL, 
MWCO = 7,000 Da) (Pierce). The average extent of labe-
ling for HisSUMO-R2C1 was estimated to be four biotin 
molecules per 1  mol of protein using the HABA assay, 
a measurement of the extent of biotinylation, as per the 
manufacturer’s protocol. Biotin-R2C1 was stored at 
−20°C in 25% glycerol.
For the pull-down assay in Figure  4c, wild type or 
mutant GST-SD2 (5  μg), bound to glutathione agarose 
resin, was incubated overnight with His-Sumo-R2-C1 
(12.5 μg). Pull down samples were washed 3× in Triton 
IP buffer and 1× in PBS prior to SDS-PAGE. Proteins 
were detected by Coomassie G-250 (Gel Code Blue, 
Pierce). 1 μg of SD2 or R2-C1 was included as a gel load-
ing (input) control.
Affinity determination and competition assays
Apparent binding affinity (Kd) was determined by immo-
bilizing 0.5  µg of SD2 diluted in 75  µL PBS for 16  h at 
4°C on 96-well Immulon 2B high binding plates (Thermo 
Scientific). Plates were blocked for 1 h at 25°C in Super-
Block T20 (TBS) Blocking buffer (Thermo Scientific). 
Concentrations of Biotin-R2C1 diluted in TBS-1 (20 mM 
Tris HCl, 150 mM KCl, 0.5% Triton X-100, pH 7.9) with 
0.5% bovine serum albumin (BSA) were added from 0 to 
1,778 nM for a total of 11 concentration points for 1 h at 
25°C. Unbound protein was removed with four washes 
in TBS-2 (20  mM Tris HCl, 300  mM KCl, 0.5% Triton 
X-100, pH 7.9). High Sensitive NeutrAvidin-HRP was 
added at a dilution of 1:40,000 in TBS-3 (25  mM Tris 
HCl, 8.25 mM Tris Base, 154 mM NaCl, 2% BSA, 0.05% 
Tween-20) for 1  h at 25°C. Excess SUMO antibody was 
removed with 4 washes in TBS-T (25  mM Tris HCl, 
137 mM NaCl, 2.7 mM KCl, 0.1% Tween-20). TMB sub-
strate (Pierce) was added for 15 min and quenched with 
0.18  M H2SO4. Absorbance was measured at 450  nm 
using a SpectraMax M5 microplate reader. The Kd was 
calculated using GraphPad Prism 4.0 using a hyperbolic 
fit with a non-zero intercept (∆A  =  ∆Amax*[R2C1]/
(Kd + [R2C1]). ∆A = absorbance change; ∆Amax = max-
imum absorbance change; [R2C1]  =  R2C1 concentra-
tion. For competition ELISAs, 100 ng of Biotin-R2C1 was 
incubated for 1 h at 25°C with unlabeled R2C1 (1–10 µg), 
and processed as described above.
High‑throughput screening
Primary screen
Initial assay development was performed in 96-well 
Immulon 2B high-binding plates (Thermo Scientific). The 
assay was then optimized for high-throughput screening 
in 384-well plates.  20,000 compounds (ChemDiv) were 
screened in the Center for Chemical Genomics at the 
University of Michigan. All reagent additions were per-
formed using Thermo Labsystems Multidrop, and plate 
washes were performed using Bio Tek EL406 washer/
aspirator. 150  ng of SD2 diluted in PBS (pH, 7.4) was 
immobilized for 16  h at 4°C on 384-well high-binding 
plates (Perkin Elmer). Unbound protein was removed 
with two washes of PBS (pH 7.4). Plates were blocked 
for 1 h at 25°C in SuperBlock T20 (TBS) Blocking buffer 
(Thermo Scientific), followed by two washes with PBS 
(pH 7.4). 20  µL of buffer A (20  mM Tris HCl, 150  mM 
KCl, 0.05% Triton X-100, 0.5% BSA, pH 7.9) was added 
to all wells. 200 nL of compounds were pin-tooled (one 
per well) into columns 3–22 resulting in a final concen-
tration of 10 µM using the Biomex FX (Beckman). 200 nL 
of DMSO was added to control columns 1–2 (nega-
tive control) and 23–24 (positive control). 5 µg of unla-
beled R2C1 in 20 µL of buffer A was added to columns 
23–24 as a positive control for inhibition. After 30  min 
at 25°C, 10  ng of Biotin-R2C1 in 10  µL of buffer A was 
added to all wells and incubated for 1 h at 25°C. Unbound 
protein was removed with three washes (buffer A sup-
plemented with 300  mM KCl and 0.5% Triton X-100). 
40  µL of 1:40,000 NeutrAvidin-HRP diluted in TBS-3 
was added to all wells and incubated for 45 min at 25°C. 
Plates were washed three times in TBS-T, followed by 
the addition of 20  µL of TMB substrate for 5  min. The 
TMB reaction was quenched with 20 µL 0.18 M H2SO4. 
Absorbance was measured at 450 nm using an automated 
PHERAstar plate reader (BMG Labs). Hits were defined 
as percent inhibition greater than 3 standard deviations 
(3 SD) from the mean of the negative control for inhibi-
tion (159 actives). Additional active samples based on 
percent effect values and standard deviation values were 
also analyzed (6 and 15 samples, respectively).
Dose response and hit selection criteria
Dose–response confirmation (180 compounds) was per-
formed following the ELISA screening platform. Com-
pound dilutions of 100, 59.8, 35.9, 21.5, 12.9, 7.69, 4.61, 
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and 2.70 µM were delivered using the Mosquito X1 (TTP 
Labtech) in duplicate. Compounds with at least 30% inhi-
bition and a pIC50 of 3.5 were considered active (74 com-
pounds). Compounds with greater than 22% promiscuity 
and less than 60% efficacy were removed. The application 
of these selection criteria resulted in 36 compounds. IC50 
values were calculated with GraphPad Prism 4.0 using 
nonlinear regression and the log (inhibitor) vs. response, 
variable slope equation. Clustering was performed using 
DataMiner by the Tripos algorithm OptiSim under the 
criteria of 65% or greater similarity.
Dose response with fresh powder
32 of the 36 hits from the primary screen were available 
for purchase from ChemDiv and were diluted in DMSO 
and stored at −20°C. 150  ng of SD2 diluted in 25  μL 
PBS was immobilized for 16 h at 4°C on 384-well high-
binding plates (Perkin Elmer). Following blocking, serial 
compound dilutions of 1,000, 300, 100, 30, 10, 3, 1, and 
0.3  μM were delivered in triplicate and incubated for 
30 min at 25°C. 10 ng of biotin-R2C1 was added (1.5 ng 
in Figure 4) and incubated for 1 h at 25°C then the ELISA 
was completed as described in primary screen. 27 of 
the 32 compounds were confirmed as active hits. Com-
pounds with an IC50 of less than 30 μM were prioritized 
(nine compounds). The IC50 values were calculated using 
GraphPad Prism with nonlinear regression and the log 
(inhibitor) vs. response, variable slope equation.
DTT and reversibility experiments
After plating 150 ng SD2, 1 mM DTT was added and was 
present throughout the assay. CCG-17444 was added at a 
concentration of 75 μM prior to addition of 1.5 ng biotin-
R2-C1. To test reversibility, wells were washed five times 
for 2 min each with buffer A after a 30-min incubation of 
75 μM CCG-17444 with SD2, prior to addition of biotin 
R2-C1. Biotinylated R2-C1 was detected with neutravidin 
HRP as described above. Absorbance was measured at 
450 nm using a Tecan safire2 microplate reader.
Neurite outgrowth experiments
P19‑derived neurons
P19 neurons were generated by transfection of pluri-
potent P19 embryonal carcinoma cells with the neural 
basic helix-loop-helix transcription factor Ngn2. P-19 
derived neurons express neuronal markers, adopt a neu-
ronal morphology, and are electrically excitable [21]. 
A GFP expression vector is included in the transfection 
and readily enables the identification of the transfected 
cells. GFP is present both in the cell body and in neur-
ites. For neurite length measurements, the length of the 
longest neurite per cell (ca. 3× cell body or 50 μm) was 
measured; GFP positive neurites are positive for the axon 
marker Tau [16] and the neuron specific tubulin TuJ1 
[21, 22]. P19 cells, grown in minimal essential medium-α 
supplemented with 7.5% calf serum, 2.5% fetal bovine 
serum, and penicillin–streptomycin were plated the day 
before transfection to a density of 2 × 105 cells/well of a 
12-well dish and transfected the next day with 2.5 µg of 
total DNA (0.75 µg of Ngn2, 0.75 µg of GFP, and 1 µg of 
pUI4/UI5 RNAi expression vectors). In Figure 5, 1.25 µg 
of control or an SD2 expression vector (SD2 amino acids 
1,768–1,986) was included with Ngn and GFP. RNAi 
vectors targeting POSH and Shroom3, as well as con-
trol luciferase RNAi vectors, have been described previ-
ously (CS2 Vector Resource, RRID:nif-0000-3027) [14, 
16, 43, 44]. 4–6  h after transfection, cells were re-split 
1:5 or 1:6 to laminin-coated dishes (2 μg/ml, Invitrogen). 
18–20 h later, the cells were transferred into Opti-mem 
supplemented with 1% FBS and penicillin–streptomycin. 
CCG-17444 was added 48  h after transfection at final 
concentration of 25 μM (Figures 3, 5). 72 h after trans-
fection, cells were fixed in 3.7% formaldehyde in PBS and 
stained for GFP to identify transfected cells [14, 16, 21]. 
Similar results are obtained when neurite length is deter-
mined by staining for GFP or neuron specific markers.
Cerebellar granule neurons
CGNs were isolated and plated in the presence or 
absence of Nogo66 and neurite length determined 30  h 
post-plating, as described [9, 14, 45, 46]. All care and 
procedures for mice were performed in accordance with 
the guidelines and approval of the University of Michi-
gan University Committee on Use and Care of Ani-
mals. 12-well dishes (Corning) were coated with 10 μg/
ml poly-l-lysine for 4  h then overnight with 2  μg/ml 
laminin at room temperature, or laminin plus bacteri-
ally expressed His-SUMO Nogo66 (0.75 μg/cm2) at 4°C. 
Postnatal d8 cerebellar granule neurons (CGNs) were 
nucleofected as described previously with a total of 6 μg 
DNA [14]. 6  h post nucleofection, Y-27632 (10  μM, 
Calbiochem, San Diego, CA, USA), a ROCK 1/2 inhibi-
tor, or CCG-17444 (25 μM of 3347-0032, ChemDiv, San 
Diego, CA, USA), were added to CGNs in culture media 
[DMEM (Invitrogen) supplemented with 2% B27 (Inv-
itrogen), and 1% penicillin/streptomycin (Invitrogen)]. 
Cells were fixed in 3.7% formaldehyde in PBS 24 h post 
inhibitor addition. Cells were stained with anti-GFP 
primary antibody [Molecular Probes (Invitrogen) Cat# 
A11122 RRID:AB_221569] followed by detection with 
Alexa Fluor 488 goat anti-rabbit (Life Technologies Cat# 
A11034 RRID:AB_10562715).
Measurement of neurite length
Photographs of GFP-positive neurons were imaged with 
a digital camera; the length of the longest neurite per 
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cell (50  μm or greater, ~3× the cell body) was meas-
ured using the polyline function in MicroSuite Special 
Edition imaging software. For assessment of inhibition 
by Nogo66, neurites less than 50  μm were also meas-
ured. At least 100 neurons per condition per experiment 
were quantitated for neurite length in three independent 
experiments.
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